Skip to main navigation Skip to search Skip to main content

T-cell responses to SARS-CoV-2 vaccinations in adults with Down syndrome–a prospective cohort study

  • Lobke C. M. Hensen
  • , Bianca M. M. Streng
  • , Femke van Wijk
  • , Stefan Nierkens
  • , Rob S. van Binnendijk
  • , Anne-Marie Buisman
  • , Antonia M. W. Coppus
  • , Corine H. Geurts van Kessel
  • , Gert de Graaf
  • , Fiona R. van der Klis
  • , Regina Lamberts
  • , Gestur Vidarsson
  • , Tracy J. Ruckwardt
  • , Esther de Vries
  • , Rory D. de Vries
  • , Michel E. Weijerman
  • , Daniel M. Weinberger
  • , Joanne G. Wildenbeest
  • , Louis J. Bont
  • , Eveline M. Delemarre*
  • *Corresponding author for this work
  • Utrecht University
  • National Institute of Public Health and the Environment
  • Radboud University Nijmegen
  • Erasmus University Rotterdam
  • Foundation Stichting Down Syndroom
  • Sanquin Blood Supply Foundation
  • National Institutes of Health
  • Tilburg University
  • Jeroen Bosch Ziekenhuis
  • Alrijne Hospital
  • Yale University

Research output: Contribution to journalArticleAcademicpeer-review

26 Downloads (Pure)

Abstract

Down syndrome (DS) is associated with immune dysfunction, which led to higher hospitalization and mortality rates during the COVID-19 pandemic. We previously showed that antibody concentrations were lower in adults with DS after primary SARS-CoV-2 vaccination. However, knowledge on cellular vaccine-induced responses in DS is limited. Here, we investigated the T-cell response induced by SARS-CoV-2 vaccination in adults with DS. We included adults with DS and healthy controls (HC) between 18 and 64 years following primary (mRNA and vector) and booster (mRNA) SARS-CoV-2 vaccination. Using flow cytometry, SARS-CoV-2-specific T cells were analyzed after spike peptide re-stimulation. Additionally, interferon-gamma (IFNγ) production by SARS-CoV-2-specific T cells was measured with an IFNγ release assay (IGRA) after antigen stimulation. We observed major deficits in naive CD4+ and CD8+ T cells in adults with DS as previously described. However, overall there was no difference in the percentage of SARS-CoV-2-specific T cells or IFNγ production by these cells after primary vaccination, albeit with vaccine-specific differences. IFNγ concentrations measured by IGRA after primary vaccination were comparable between DS and HC. Booster vaccination increased SARS-CoV-2-specific T cells in HC but not in DS, while IFNγ release (IGRA) increased to similar concentrations. In conclusion, we show that while functional T-cell responses (IFNγ production) are comparable after primary and booster vaccination, the magnitude (percentage of SARS-CoV-2-specific T cells) may be lower after mRNA vaccination. We previously showed lower antibody concentrations and profound abnormalities in the naive T-cell compartment, warranting further investigation into T-cell-B-cell-interactions after vaccination in adults with DS. Clinical trial registration: NCT05145348 https://www.clinicaltrials.gov/study/NCT05145348?locStr=Netherlands&country=Netherlands&cond=Down%20Syndrome&term=SARS-CoV-2%20Vaccination&rank=1. Start date: 2021–02-03.
Original languageEnglish
Article number2583416
JournalHuman vaccines & immunotherapeutics
Volume21
Issue number1
DOIs
Publication statusPublished - 2025

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • COVID-19
  • Down syndrome
  • IFNγ
  • SARS-CoV-2
  • T cells
  • mRNA and vector vaccines

Fingerprint

Dive into the research topics of 'T-cell responses to SARS-CoV-2 vaccinations in adults with Down syndrome–a prospective cohort study'. Together they form a unique fingerprint.

Cite this